Article Information
History
- October 20, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Karlijn Hummelink1,2,*,
- Vincent van der Noort3,
- Mirte Muller2,
- Robert D. Schouten2,
- Michel M. van den Heuvel2,4,
- Daniela S. Thommen5,
- Egbert F. Smit2,6,
- Gerrit A. Meijer1 and
- Kim Monkhorst1,*
- 1Department of Pathology, Division of Diagnostic Oncology,
- 2Department of Thoracic Oncology, Division of Medical Oncology,
- 3Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands,
- 4Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands,
- 5Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands,
- 6Department of Pulmonary Diseases, Leiden University Medical enter, Leiden, The Netherlands
- ↵*Corresponding authors:
Email: k.monkhorst{at}nki.nl (KM) and k.hummelink{at}nki.nl (KH)
Posted October 20, 2023.
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in Non-Small Cell Lung Cancer
